Baseline demographics and characteristics*
| T1D integrated | T2D insulin-naïve | T2D previously treated with insulin | ||||
| Glargine (n=64) | BIL (n=118) | Glargine (n=59) | BIL (n=117) | Glargine (n=53) | BIL (n=110) | |
| Age, years | 37.4±12.2 | 40.1±12.3 | 58.4±10.1 | 59.4±9.6 | 62.1±10.2 | 61.6±8.6 |
| Male, n (%) | 40 (62.5) | 67 (56.8) | 36 (61.0) | 72 (61.5) | 31 (58.5) | 66 (60.0) |
| Weight, kg | 79.1±17.8 | 79.0±14.8 | 93.9±19.5 | 94.8±17.8 | 93.5±16.9 | 93.0±16.0 |
| Body mass index, kg/m2 | 26.4±4.0 | 26.7±3.6 | 32.5±5.4 | 32.9±5.1 | 32.2±5.1 | 32.0±5.0 |
| Diabetes duration, years | 15.4±10.7 | 17.7±12.2 | 11.6±7.0 | 12.0±7.1 | 12.6±7.4 | 12.6±6.7 |
| Lipid-lowering medication, n (%) | 10 (15.6) | 24 (20.3) | 41 (69.5) | 84 (71.8) | 37 (69.8) | 76 (69.1) |
| HbA1c, % | 7.9±1.1 | 7.9±1.2 | 8.3±1.1 | 8.3±0.9 | 7.4±0.8 | 7.4±0.8 |
| K-18, U/L† | 183.0±15.8 | 148.2±11.6 | 246.9±27.8 | 223.8±19.3 | 219.2±23.9 | 207.1±16.1 |
| ELF score† | 8.24±0.10 | 8.36±0.07 | 9.14±0.11 | 9.14±0.08 | 9.12±0.10 | 9.20±0.07 |
| ALT, IU/L | 20±11 | 21±11 | 31±21 | 30±15 | 26±12 | 26±13 |
| AST, IU/L | 21±7 | 22±9 | 26±13 | 25±12 | 24±10 | 23±8 |
| LFC (%)† | 3.41±0.41 | 3.04±0.30 | 12.73±1.14 | 13.25±0.81 | 9.96±1.09 | 10.39±0.75 |
| Triglycerides, mg/dL | 1.01±0.60 | 1.06±0.66 | 1.70±0.74 | 1.96±1.07 | 1.75±0.89 | 1.77±0.87 |
| LDL-cholesterol, mg/dL | 2.79±0.64 | 2.74±0.77 | 2.30±0.70 | 2.28±0.90 | 2.37±0.79 | 2.43±0.86 |
| HDL-cholesterol, mg/dL | 1.57±0.42 | 1.61±0.39 | 1.20±0.27 | 1.20±0.32 | 1.18±0.33 | 1.21±0.3 |
No statistically significant treatment differences in any of the listed baseline parameters within each population.
Data are mean±SD except where indicated.
*Adapted from Cusi et al.7
†Least squares mean±SE.
n, number of patients randomized; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BIL, basal insulin peglispro; ELF, enhanced liver fibrosis; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; K-18, cytokeratin-18; LDL, low-density lipoprotein; LFC, liver fat content; T1D, type 1 diabetes; T2D, type 2 diabetes.